Research & Critiques
Thimerosal is an organic compound that is 49.6% ethyl mercury by weight. Developed as an antiseptic and antibacterial product, pharmaceutical companies began to use thimerosal in vaccines in the 1930s for the intended purpose of preventing bacterial contamination due to repeated needle punctures into multi-dose vials of vaccine. Below are links to abstracts from over 190 research studies detailing the effects of including thimerosal in vaccines.
Geier 2009 – Mitochondrial dysfunction, impaired oxidative-reduction activity, degeneration, and death in human neuronal and fetal cells induced by low-level exposure in thimerosal and other metal compounds
Geier 2014 – The risk of neurodevelopment disorders following a Thimerosal-preserved DTaP formulation in comparison to its Thimerosal-reduced formulation in the vaccine adverse event reporting system (VAERS)
Geier 2015 – A Case-Control Study Evaluating the Relationship Between Thimerosal-Containing Haemophilus influenza Type b Vaccine Administration and the Risk for a Pervasive Developmental Disorder Diagnosis in the United States
Geier 2016 – A longitudinal cohort study of the relationship between Thimerosal-containing hepatitis B vaccination and specific delays in development in the United States: Assessment of attributable risk and lifetime care costs
Geier 2017 – Increased Risk for an Atypical Autism Diagnosis Following Thimerosal-containing Vaccine Exposure in the United States: A Prospective Longitudinal Case-Control Study in the Vaccine Study Datalink
Ida-Eto 2013 – Prenatal exposure to organomercury, thimerosal, persistently impairs the serotonergic and dopaminergic systems in the rat brain: Implications for association with developmental disorders